Cost-utility analysis of curative and maintenance repetitive transcranial magnetic stimulation (rTMS) for treatment-resistant unipolar depression: a randomized controlled trial protocol
Samuel Bulteau,Andrew Laurin,Christelle Volteau,Cécile Dert,Lydie Lagalice,Solène Schirr-Bonnans,Nicolas Bukowski,Marie Guitteny,Luc Simons,Clémence Cabelguen,Anne Pichot,Fabienne Tessier,Annabelle Bonnin,Adeline Lepage,ACOUSTIM Investigators Group,HUGOPSY Network,Jean-Marie Vanelle,Anne Sauvaget,Valery-Pierre Riche,Jérôme Attal,Jean-Marie Batail,René Benadhira,Djamila Bennabi,Caroline Berjamin,Maxime Bonnin,Noomane Bouaziz,Jérôme Brunelin,Maxime Bubrovszky,Benjamin Calvet,Irina-Alexandra Catana,Macarena Cuenca,Gaelle Dall' Igna,Dominique Drapier,Laurine Egreteau,Wissam El-Hage,Filipe Galvao,Ghina Germaneau,Bénédicte Gohier,Emmanuel Haffen,Ghassan Harika,Guillaume Ifrah,Némat Jaafari,Isabelle Jalenques,Dominique Januel,Redwan Maatoug,Bruno Millet,Clément Nathou,Benjamin Petit,Damien Pierre,Marion Plaze,Emmanuel Poulet,Gabriel Robert,Maud Rotharmel,Marine Rozet,David Szekely,Simon Taib,Benoît Trojak,Antoine Yrondi
DOI: https://doi.org/10.1186/s13063-020-04255-9
IF: 2.728
2020-04-05
Trials
Abstract:Background: Depression is a debilitating and costly disease for our society, especially in the case of treatment-resistant depression (TRD). Repetitive transcranial magnetic stimulation (rTMS) is an effective adjuvant therapy in treatment-resistant unipolar and non-psychotic depression. It can be applied according to two therapeutic strategies after an initial rTMS cure: a further rTMS cure can be performed at the first sign of relapse or recurrence, or systematic maintenance rTMS (M-rTMS) can be proposed. TMS adjuvant to treatment as usual (TAU) could improve long-term prognosis. However, no controlled study has yet compared the cost-effectiveness of these two additional rTMS therapeutic strategies versus TAU alone. Methods/design: This paper focuses on the design of a health-economic, prospective, randomized, double-blind, multicenter study with three parallel arms carried out in France. This study assesses the cost-effectiveness of the adjunctive and maintenance low frequency rTMS on the right dorsolateral prefrontal cortex versus TAU alone. A total of 318 patients suffering from a current TRD will be enrolled. The primary endpoint is to investigate the incremental cost-effectiveness ratio (ICER) (ratio costs / quality-adjusted life-years [QALY] measured by the Euroqol Five Dimension Questionnaire) over 12 months in a population of patients assigned to one of three arms: systematic M-rTMS for responders (arm A); additional new rTMS cure in case of mood deterioration among responders (arm B); and a placebo arm (arm C) in which responders are allocated in two subgroups: sham systematic M-rTMS and supplementary rTMS course in case of mood deterioration. ICER and QALYs will be compared between arm A or B versus arm C. The secondary endpoints in each three arms will be: ICER at 24 months; the cost-utility ratio analysis at 12 and 24 months; 5-year budget impact analysis; and prognosis factors of rTMS. The following criteria will be compared between arm A or B and arm C: rates of responders; remission and disease-free survival; clinical evolution; tolerance; observance; treatment modifications; hospitalization; suicide attempts; work stoppage; marital / professional statues; and quality of life at 12 and 24 months. Discussion: The purpose of our study is to check the cost-effectiveness of rTMS and we will discuss its economic impact over time. In the case of significant decrease in the depression costs and expenditures associated with a good long-term prognosis (sustained response and remission) and tolerance, rTMS could be considered as an efficient treatment within the armamentarium for resistant unipolar depression. Trial registration: ClinicalTrials.gov, NCT03701724. Registered on 10 October 2018. Protocol Amendment Version 2.0 accepted on 29 June 2019.